English Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil

Archivos en Investigación del Cáncer

  • ISSN: 2254-6081
  • Índice h de la revista: 13
  • Puntuación de cita de revista: 3.58
  • Factor de impacto de la revista: 3.12
Indexado en
  • Infraestructura Nacional de Conocimiento de China (CNKI)
  • CiteFactor
  • OCLC-WorldCat
  • Publón
  • Fundación de Ginebra para la Educación e Investigación Médica
  • Google Académico
  • Laboratorios secretos de motores de búsqueda
Ver más
Comparte esta página

Abstracto

Inhibition of the Cyclin-Dependent Kinases (CDK) 4/6 as Therapy for Estrogen Receptor Positive Breast Cancer

Aurelio B Castrellon, Steven M Nguyen and Luis E Raez

Endocrine therapy (ET) is the usual first-line therapy for patients with hormone receptor-positive metastatic breast cancer (HR+MBC). However, resistance to ET frequently occurs during the course of treatment. Cellular pathways involved in cell proliferation are targets for new drugs that interfere with development of resistance to ET. Cyclin-dependent kinases (CDKs) are a subgroup of serine/ threonine kinases that play a key role in regulating cell cycle progression. In this review, we discuss the currently approved and under investigation CDK 4/6 inhibitors, in addition to their preclinical data and clinical trials that demonstrated their benefit in the treatment of HR+ breast cancer.

Descargo de responsabilidad: este resumen se tradujo utilizando herramientas de inteligencia artificial y aún no ha sido revisado ni verificado